Search clinical trials for: A166

Total 58 results

Fudan University

Not yet recruiting

HER2-positive Breast Cancer Project Initiated by Investigators

Breast Cancer
Klus Pharma Inc.

Completed

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Cervical Cancer | Head and Neck Cancer | Mucoepidermoid Carcinoma | Pancreatic Cancer | Recurrent Prostate Cancer | Lung Cancer | Rectal Cancer | Solid Tumor | Prostate Cancer | Cholangiocarcinoma | Bile Duct Cancer | Recurrent Ovarian Carcinoma | Bladder Cancer | Skin Cancer | HER2-positive Breast Cancer | Rare Diseases | Colo-rectal Cancer and other conditions

United States
Sichuan Kelun Pharmaceutical Research Institute...

Recruiting

A Study of A166 in Patients With Advanced Solid Malignant Tumors

Breast Cancer

China
AlaMab Therapeutics (Shanghai) Inc.

Recruiting

Study to Evaluate the Safety and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury

Acute Spinal Cord Injury

China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Completed

An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

Classical Hodgkin Lymphoma

China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Triple-negative Breast Cancer and HR+/HER2- BC

China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Completed

KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Recurrent or Metastatic

China
MedImmune LLC

Completed

A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes

Type 2 Diabetes

United States
Rigshospitalet, Denmark

Completed

The Effect of Mobilized Stem Cell by G-CSF and VEGF Gene Therapy in Patients With Stable Severe Angina Pectoris

Ischemic Heart Disease

Denmark
Terumo Europe N.V.

Recruiting

Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma. (HOMIE-166)

Hepatocellular Carcinoma

Germany
Laboratoires URGO

Completed

Assessment of Efficacy & Tolerance of Urgo 310 3166 Dressing in Local Venous or Mixed Leg Ulcers (CASSIOPEE)

Ulcers, Leg

France
Poniard Pharmaceuticals

Terminated

A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma

Multiple Myeloma
UMC Utrecht
Erasmus Medical Center; Terumo Corporation

Recruiting

Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma (iHEPAR)

Hepatocellular Carcinoma Non-resectable

Netherlands
UMC Utrecht
Erasmus Medical Center; Dutch Cancer Society; Quirem Medical B.V.

Completed

HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients

Hepatocellular Carcinoma | Hepatocellular Carcinoma Non-resectable

Netherlands
Radboud University Medical Center
Terumo Medical Corporation; Quirem Medical B.V.

Recruiting

Percutaneous Holmium Injection in Pancreatic Cancer (SLOTH-2a)

Pancreas Cancer

Netherlands
UMC Utrecht

Completed

Radioactive Holmium Microspheres for the Treatment of Liver Metastases (HEPAR)

Liver Tumors | Liver Metastasis

Netherlands
Sichuan Kelun Pharmaceutical Research Institute...

Recruiting

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer

China
Leiden University Medical Center
Medtronic; ZonMw: The Netherlands Organisation for Health Research and Development and other collaborators

Completed

Holmium Radioembolization as Adjuvant Treatment to RFA for Early Stage HCC: Dose Finding Study (HORA EST HCC)

HCC | Early Stage HCC

Netherlands
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone

Sarcoma | Metastatic Cancer

United States
Merck Sharp & Dohme LLC

Completed

Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)

Solid Tumor
Institute of Cardiology, Warsaw, Poland
Medical University of Warsaw; Center of Oncology, Warsaw, Poland; Ministry of... and other collaborators

Completed

Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered Percutaneously in No-option CAD Patients; a Controlled Trial (VIF-CAD)

Coronary Artery Disease

Poland
Erasme University Hospital
Terumo Europe N.V.

Completed

Safety and Feasibility of Radioembolization Using Ho-166 in Patients With Unresectable Hepatocellular Carcinoma (RETOUCH)

Hepatocellular Carcinoma

Belgium
UMC Utrecht

Terminated

Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors (HIT)

Head and Neck Neoplasms | Radioisotopes

Netherlands
UMC Utrecht

Completed

Radioactive Holmium Microspheres for the Treatment of Unresectable Liver Metastases (HEPAR-2)

Liver Neoplasms

Netherlands
Terumo Europe N.V.

Completed

Holmium-166 Retrospective Collection of Real-World Data (RECORD)

Hepatocellular Carcinoma | Metastatic Cancer

Netherlands, Germany, Switzerland, Belgium, Spain, Portugal, Italy
UMC Utrecht

Completed

Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study (HEPAR_Plus)

Neuroendocrine Tumors

Netherlands
Beijing Chest Hospital
Shandong Chest Hospital; Zhengzhou Sixth People's Hospital

Active, not recruiting

Early Bactericidal Activity Safety Pulmonary Tuberculosis Pyrifazimine (TBI-166)

Sensitive Pulmonary Tuberculosis

China
UMC Utrecht

Unknown

Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization (SIM)

Liver Diseases | Digestive System Neoplasms | Neoplasm Metastasis | Colorectal Neoplasms

Netherlands
Poniard Pharmaceuticals

Terminated

Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma

Multiple Myeloma

United States, Canada
Teva Branded Pharmaceutical Products R&D, Inc.
PPD

Completed

Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils

Asthma

United States, Argentina, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Romania, Russian Federation, South Africa, Spain, Turkey, Ukraine
Mati Therapeutics Inc.

Completed

Safety and Intraocular Lowering Effect of Delivery of Travoprost Evolute® in Subjects With Elevated Intraocular Pressure

Elevated Intraocular Pressure (IOP)

United States
MediciNova
Wake Forest University Health Sciences

Completed

Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) (IBU-ALS-1201)

Amyotrophic Lateral Sclerosis

United States
UCB Pharma SA

Completed

Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy

Generalized Epilepsy
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Active, not recruiting

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Recurrent or Metastatic

China
Atlantic Pharmaceuticals Ltd

Completed

Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics

Pouchitis

United States, Belgium, Canada, France, Ireland, Israel, Italy, Netherlands, Switzerland, United Kingdom
Italian Society of Nephrology
European Commission; Memorial University of Newfoundland

Terminated

Bicarbonate v Saline to Prevent Contrast Nephropathy

Kidney Failure, Acute | Contrast Media

Italy
Bayer

Completed

FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period (FREEDOM)

Overactive Bladder

South Africa
Genuine Research Center, Egypt
Hikma Pharmaceuticals LLC

Completed

Bioequivalence Study of Budesonide From Ekmasonid 9 mg Extended Release FCT (Hikma Pharma, Egypt) Versus Uceris 9 mg Extended Release Tablets (Man. for: Salix Pharm., a Division of Valeant Pharm. LLC, USA, by: Cosmo S.P.A., Italy by License of Cosmo Tech. Ltd., Ireland, Product of France)

Healthy

Egypt
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Terminated

Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma

Glioblastoma | Glioblastoma Multiforme

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Poniard Pharmaceuticals

Completed

Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
MediciNova

Active, not recruiting

Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS

Pneumonia, Viral

United States
MediciNova

Recruiting

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS (COMBAT-ALS)

Amyotrophic Lateral Sclerosis

United States, Canada
MediciNova
Massachusetts General Hospital; South Shore Neurologic Associates

Completed

A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
MediciNova
National Institute of Neurological Disorders and Stroke (NINDS); National Institutes... and other collaborators

Completed

Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis

Multiple Sclerosis, Secondary Progressive | Multiple Sclerosis, Primary Progressive

United States
MediciNova

Completed

Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers

Healthy Volunteers

United States
MediciNova

Completed

Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers

Healthy Volunteers

United States
University Health Network, Toronto

Recruiting

RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine (RECLAIM)

Long COVID | Post Acute Sequelae of COVID-19 | Post COVID Condition

Canada
University of California, Los Angeles
National Institute on Alcohol Abuse and Alcoholism (NIAAA); MediciNova

Completed

Ibudilast for the Treatment of Alcohol Use Disorder

Alcohol Use Disorder

United States

Search clinical trials for: A166

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations